NEXT SCIENCE LIMITED (NXS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NXS

NXS - NEXT SCIENCE LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.105

24 Mar
2025

-0.015

OPEN

$0.11

-12.50%

HIGH

$0.11

204,816

LOW

$0.11

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-5.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx34.6 M
Book Value Per Share xxxxxxxxxxxxxxx1.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-12.1 M
Net Profit Margin xxxxxxxxxxxxxxx-46.40 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-131.82 %
Return on Invested Capital xxxxxxxxxxxxxxx-110.59 %
Return on Assets xxxxxxxxxxxxxxx-78.07 %
Return on Equity xxxxxxxxxxxxxxx-131.82 %
Return on Total Capital xxxxxxxxxxxxxxx-105.12 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-12.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx6.04

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx2.58 %
Cost of Goods Sold xxxxxxxxxxxxxxx9 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx42 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

28/01/2025

1

Speculative Buy

$0.40

280.95%

Next Science reported December quarter result, again missing Canaccord Genuity's expectations, noting a sluggish Durable Medical Equipment (DME) segment and balance sheet under pressure.

XPerience (XP) was the hero, growing 85% off a low base and one-off saline shortage, and offsetting DME weakness. The broker maintains XP will require successful clinical outcomes to warrant longer-term commercial success.

The broker notes balance sheet is very flexed with $1.7m in cash but additional capital and flawless execution will be required from here in order to stay out of the woods in the medium term.

The broker maintains a conservative to pessimistic view on Next Science in the near and medium term.

Rating retained at Speculative Buy and target price at 40c.
Access Extra Coverage Research History >

NXS STOCK CHART

FNArena News on NXS

1
Australian Broker Call *Extra* Edition – Jan 28, 2025

Jan 28 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 30, 2024

Oct 30 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 06, 2024

Aug 06 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 07, 2024

May 07 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Mar 12, 2024

Mar 12 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps